Atlas
Back to PPM Roll-Ups
Strategic Advisor·PPM Roll-Ups

Dr. Tushar Ramani

Chief Executive Officer at Integrated Dermatology

South Florida, USA

DT
LinkedIn
Why they matter

Serial CEO of four consecutive PE-backed physician practice roll-ups (Anesthetix, CRH Medical, Women's Care, Integrated Dermatology) with rare cross-specialty rollup playbook expertise.

Background

Dr. Tushar Ramani is a physician-executive with 30+ years in healthcare services, trained as an anesthesiologist (Sidney Kimmel/Jefferson Medical College; residency at Mount Sinai). He built his career converting clinical practice groups into scaled, PE-backed platforms — co-founding Anesthetix Management, then serving as CEO of TeamHealth's Anesthesia Division, CRH Medical Corporation, MedOptions, and Women's Care — before becoming CEO of Integrated Dermatology in March 2024.

Notable deals

  • 2000
    Co-founded Anesthetix Management, an anesthesiology and pain-management platform later backed by Summit Partners and scaled nationally before its sale to TeamHealth Holdings
  • 2019
    Appointed CEO of CRH Medical Corporation (NYSE American/TSX-listed anesthesia services roll-up), succeeding Edward Wright
  • 2022
    Named CEO of Women's Care, a national OB-GYN physician group, following an extensive national search
  • 2024
    Named CEO of Integrated Dermatology, the country's largest independent dermatology provider platform

Call-prep brief

Background

  • Anesthesiologist by training (Jefferson Medical College; Mount Sinai residency) who pivoted to healthcare services operating/investing 20+ years ago.
  • Career arc: co-founded Anesthetix (2000) → sold to TeamHealth, ran TeamHealth's Anesthesia Division to $300M+ revenue → Summit Partners Executive-in-Residence → CEO of MedOptions → CEO/Chairman of CRH Medical (2019-2022) → CEO of Women's Care (2022-2024) → CEO of Integrated Dermatology (since March 2024).

Current focus

  • Growing Integrated Dermatology's affiliated-physician network, adding technology/support infrastructure, and positioning the platform for continued consolidation in dermatology.

What he cares about

  • Physician alignment and culture in roll-ups — repeatedly emphasized keeping clinicians bought into corporate/PE growth goals rather than just financial engineering.
  • Operating leverage and scaling shared services across a fragmented specialty.

Recent moves

  • Left Women's Care CEO role in early 2024 to take Integrated Dermatology CEO seat — a lateral move between specialty rollups, notable to any investor benchmarking OB-GYN vs. dermatology platform economics.

Potential sensitivities

  • He has now run four consecutive sponsor-backed platforms in relatively short tenures (avg. ~2-3 years each) — worth probing why each transition happened (sale, board change, personal choice).
  • May have ongoing non-competes/board relationships with CRH (Well Health) or Women's Care.

Questions to ask

  1. What made the anesthesia/GI, OB-GYN, and dermatology rollup playbooks similar vs. different operationally?
  2. What physician-alignment mechanisms (comp, equity, governance) worked best across his platforms, and which failed?
  3. What's his read on remaining consolidation runway and multiple compression risk in dermatology specifically?

Outreach draft

Subject
Quick call on physician platform rollups?
Dr. Ramani, I'm reaching out from a private equity team studying physician practice consolidation across specialties. Your run leading Anesthetix, CRH Medical, Women's Care, and now Integrated Dermatology gives you a rare cross-specialty view of what makes these platforms work — and where they break. We'd value 30 minutes to hear your perspective on physician alignment, governance structures, and where you see the best remaining opportunities for consolidation, particularly in dermatology and adjacent specialties. Would you have time for a call in the next couple of weeks? Happy to work around your schedule. Best, [Placeholder Name]

Linked companies

Sources